Telomir Pharmaceuticals (NASDAQ: TELO) has announced the publication of peer-reviewed preclinical data in Advances in Redox Research demonstrating that Telomir-Zn, the company's lead small-molecule therapeutic, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson's disease model. The findings, which include reduced oxidative stress, lower hepatic copper burden, and improved liver function markers, support the biological activity of Telomir-Zn in Wilson's disease and expand the company's scientific validation as it advances its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation.
Wilson's disease is a genetic disorder characterized by copper accumulation in the liver and brain, leading to oxidative stress and organ damage. The preclinical study, detailed in the peer-reviewed journal, highlights Telomir-Zn's potential to address the underlying mechanisms of the disease by modulating intracellular metal homeostasis and redox balance. According to the company, the results provide a strong foundation for further development of Telomir-Zn in Wilson's disease and reinforce the therapeutic platform's versatility.
The full press release is available at https://ibn.fm/fOSNo. Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company's lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
These latest data are significant because they not only support the potential of Telomir-Zn in Wilson's disease but also validate the broader applicability of the company's technology platform beyond its primary focus on triple-negative breast cancer. The ability to address multiple indications with a single therapeutic candidate could enhance the company's pipeline value and attract further research interest. For investors, the publication in a peer-reviewed journal adds credibility to the preclinical findings and may inform future clinical trial design.
More information on Telomir Pharmaceuticals can be found in the company's newsroom at https://ibn.fm/TELO. The company's ongoing work continues to explore the potential of Telomir-Zn in various disease models, with the aim of advancing toward clinical development.
